Table of Contents

Editorial

• Effectiveness and Safety of Atezolizumab Monotherapy in Previously Treated Japanese Patients With Unresectable Advanced or Recurrent NSCLC: A Multicenter, Prospective, Observational Study (J-TAIL)

Commentary

• Comments on the Article by Miura et al.: “Comparable Clinical Benefit Between Different Subsets Selected by PD-L1 22C3 and SP142 Tests”

Original Articles:

• Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade–Resistant Advanced NSCLC
   
• Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study
   
• Interventions Designed to Increase the Uptake of Lung Cancer Screening: An Equity-Oriented Scoping Review
   
• The EGFR C797S Mutation Confers Resistance to a Novel EGFR Inhibitor CLN-081 to EGFR Exon 20 Insertion Mutations
   
• Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in BRAF Mutation-Positive NSCLC

Brief Reports

• Application of the Novel Grading System of Invasive Pulmonary Adenocarcinoma in a Real Diagnostic Scenario: A Brief Report of 9353 Cases
   
• Brief Report: Severe Pneumonitis After Combined Thoracic Radiotherapy and Osimertinib
   

JTO Clinical and Research Reports is the official open access journal of the International Association for the Study of Lung Cancer. It aims to complement the Journal of Thoracic Oncology by offering authors a gold open access publication option and publishing the following article types in particular:

• Phase I trials
• Well performed single-arm phase II trials
• Subset analyses of published trials
• Impactful retrospective Studies
• Database analysis
• Large institutional series
• High-quality case reports
• Region-specific clinical trials
• Subspecialty thoracic oncology studies
• Selected high-quality meeting reports

As an open access journal with no subscription charges, JTO CRR requires authors to pay a fee to cover the costs associated with publication. This ensures your article will be immediately and permanently free to access by everyone.